Navigation Links
Going Beyond 'Spa Day': Giving Women the Opportunity to Do Something Proactive Which May Lead to Long Term Health Benefits
Date:8/25/2008

C'elle Discovers Stem Cells Found in Menstrual Blood May Offer Long-Lasting

Therapeutic Effects for Time-Pressed Women

OLDSMAR, Fla., Aug. 25 /PRNewswire/ -- Time. It is a precious commodity. Yet most women would agree that there never seems to be enough of it. And the small amount of time a woman spends on doing something just for herself usually pales in comparison to the time she invests in others. This reality has led many women in need of quality time to seek out "quick fixes" at day spas, and most recently medical spas, where services and procedures can be costly. However, the benefits for these pricey treatments are usually fleeting, with no real long-lasting, therapeutic effects.

Now, thanks to the cutting-edge research and technology of C'elle, a service dedicated to providing women with a safe and easy method of collecting and preserving stem cells found in her menstrual fluid each month, a woman can do something positive for herself while also potentially helping her family.

In fact, the latest science has revealed that stem cells, harvested from a woman's own menstrual blood may be used in treating a number of possibly life-threatening diseases that she, a parent, a sibling or even her children may face in later years, such as osteoporosis, heart disease, stroke, Alzheimer's and Parkinson's disease.

With C'elle's affordable collection process, menstrual cells are processed and cryo-preserved (stored at a very low temperature) for potential cellular therapies that may emerge in the future. These self-renewing cells one day may even be utilized for cosmeceutical treatments, such as anti-aging therapies or sports medicine.

"C'elle offers women the unique opportunity to bring the focus back on themselves in a way that is lasting and long term without being time-consuming or invasive," said Michelle Fox Kay, Director of Marketing for C'elle. "We live in a society where women do not have a lot of time to
'/>"/>

SOURCE C'elle
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of Mr. C Causes Major Interest in the Scientific Community
2. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
3. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
4. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
5. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
6. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
7. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
8. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
9. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
10. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
11. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  A novel wearable injector slightly larger than ... for patients to self-inject prescription drugs in the large doses ... blood diseases, autoimmune deficiencies, and genetic disorders.  ... $220B by 2018, according to analysts.   Many of these drugs ...
(Date:1/14/2014)... Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a ... it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... terms of the acquisition were not disclosed. ... providing a wide range of sleep, mobility, and respiratory products ...
(Date:1/14/2014)... 2014   Oligomerix, Inc. , a privately held company ... disease (AD) and related neurodegenerative disorders, announced today the ... NY as of January 15, 2014 and ... York Medical College. Oligomerix, which is focused ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Homeostasis Effects in,Normal and Diabetic Rats --, CHICAGO, ... IIa study of the safety profile of multiple ... of,the Sodium-Glucose Transporter 2 (SGLT2) administered alone or,concomitantly ... no,discontinuations due to adverse events and no serious ...
... June 25, 2007 /PRNewswire/ -- Novagali Pharma, an,emerging ... its pivotal phase III clinical trial,positive results from ... suffering from Vernal Keratoconjunctivitis (VKC) at the,XIV Afro-Asian ... 25 2007 in Marrakech (Morocco). , VKC is ...
Cached Medicine Technology:First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 2First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 3First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 4First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 5First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 6Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 2Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 3Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 4
(Date:4/18/2014)... of your worst memories? How did it make you ... a negative personal experience, such as how sad you ... emotional distress, especially when you can,t stop thinking about ... thinking about the context of the memories, rather than ... way to alleviate the negative effects of these memories, ...
(Date:4/18/2014)... available in French . ... practice and regenerative medicine. A team led by Ludwik ... Paris Tech) and Didier Letourneur from the Laboratoire Recherche ... just demonstrated that the principle of adhesion by aqueous ... repair soft-tissue organs and tissues. This easy-to-use gluing method ...
(Date:4/17/2014)... first genetic variant specifically associated with the risk ... 10-15 per cent of all breast cancer cases. ... cancer sub-type, called invasive lobular carcinoma, gives researchers ... particular kind of breast cancer, which can be ... (Thursday) in the journal PloS Genetics , ...
(Date:4/17/2014)... the April issue of Experimental Biology and ... Drs. Rex Gaskins and Paul Kenis in the ... of the University of Illinois Urbana-Champaign describe their ... reactions underlie a variety of cell functions including ... these crucial roles in regulating normal cellular behavior, ...
(Date:4/17/2014)... Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently ... issue of Nature Reviews Microbiology , one ... McCullers, a world-renowned infectious disease specialist, and chair ... of Tennessee Health Science Center, analyzed the epidemiology ... and 1968 pandemics, as well as more recent ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2
... now widespread in just one state, but a resurgence could ... -- As the H1N1 swine flu outbreak eases to ... state, federal health officials are still urging Americans to get ... Influenza Vaccination Week," Kathleen Sebelius, Secretary of the U.S. Department ...
... , NEWBURGH, N.Y., Jan. 8 "I hope I ... need help and to offer them advice and guidance." , So said ... Mary College, is one of the many students who have made psychology ... Mount also has many students who pursue careers in education, taking a ...
... treatment with the natural compound Quercetin , FRIDAY, Jan. ... that play an important role in hepatitis C infection, and ... toxic treatments for the disease, which can lead to cirrhosis ... are interferon and ribavirin, which can cause major side effects ...
... , , - Subtle Language ... PHILADELPHIA, Jan 8 Children with autism spectrum disorders (ASDs) process ... without ASDs, and measuring magnetic signals that mark this delay may ... http://www.newscom.com/cgi-bin/prnh/20100108/DC34671 ) , Researchers at The Children,s Hospital of ...
... Jan. 8 Gilbert Hospital continued to exceed expectations in ... emergency department, patient levels remained constant compared to 2008. ... continued its success with more than 98.5% of emergency room ... minutes of arrival. Additionally, the average wait time in 2009 ...
... ... to be presented at 32nd annual San Antonio Breast Cancer Symposium , ... Los Angeles, ... biotechnology company, today announced that multiple clinical studies of the chemotherapy agent ABRAXANE® ...
Cached Medicine News:Health News:As Swine Flu Ebbs, Officials Stress Importance of Vaccine 2Health News:As Swine Flu Ebbs, Officials Stress Importance of Vaccine 3Health News:Psychology Popular Among College Students 2Health News:Psychology Popular Among College Students 3Health News:Psychology Popular Among College Students 4Health News:Psychology Popular Among College Students 5Health News:Key to Hepatitis C May Be Two Cellular Proteins 2Health News:Brain Imaging May Help Diagnose Autism 2Health News:Brain Imaging May Help Diagnose Autism 3Health News:Brain Imaging May Help Diagnose Autism 4Health News:Gilbert Hospital 2009 Emergency Department Year in Review 2Health News:Abraxis Provides Overview Of ABRAXANE Study 2Health News:Abraxis Provides Overview Of ABRAXANE Study 3
Inquire...
Inquire...
... remarkable anti-reflux valve is enclosed ... which prevents the valve from ... in sitting or reclining positions. ... and interference free ensuring uninterrupted ...
... anti-reflux valve is enclosed in ... prevents the valve from being ... sitting or reclining positions. The ... interference free ensuring uninterrupted flow ...
Medicine Products: